Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia.

Ebinger M, Witte KE, Ahlers J, Schäfer I, André M, Kerst G, Scheel-Walter HG, Lang P, Handgretinger R.

Leuk Res. 2010 Sep;34(9):1139-42. doi: 10.1016/j.leukres.2010.03.023. Epub 2010 Apr 7.

PMID:
20378168
2.

High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.

Witte KE, Ahlers J, Schäfer I, André M, Kerst G, Scheel-Walter HG, Schwarze CP, Pfeiffer M, Lang P, Handgretinger R, Ebinger M.

Pediatr Hematol Oncol. 2011 Mar;28(2):91-9. doi: 10.3109/08880018.2010.528171. Epub 2011 Jan 8.

PMID:
21214408
3.

[Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].

Popov AM, Verzhbitskaia TIu, Tsaur GA, Shorikov EV, Savel'ev LI, Tsvirenko SV, Fechina LG.

Klin Lab Diagn. 2010 Aug;(8):36-41. Russian.

PMID:
20886718
5.

Clinical significance of immunophenotypic markers in pediatric T-cell acute lymphoblastic leukemia.

Sidhom I, Shaaban K, Soliman S, Ezzat S, El-Anwar W, Hamdy N, Yassin D, Salem S, Hassanein H, Mansour MT.

J Egypt Natl Canc Inst. 2008 Jun;20(2):111-20.

6.

High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.

van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, van der Pol MA, Waisfisz Q, Ossenkoppele GJ, Schuurhuis GJ.

Clin Cancer Res. 2005 Sep 15;11(18):6520-7.

7.

[Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].

zur Stadt U, Harms DO, Schlüter S, Jorch N, Spaar HJ, Nürnberger W, Völpel S, Gutjahr P, Schrappe M, Janka G, Kabisch H.

Klin Padiatr. 2000 Jul-Aug;212(4):169-73. German.

PMID:
10994545
8.

Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.

Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, Sandlund JT, Rivera GK, Rubnitz JE, Ribeiro RC, Pui CH, Campana D.

Blood. 2000 Oct 15;96(8):2691-6.

9.

[Cells antigens' expression modulation during induction treatment of childhood acute lymphoblastic leukemia].

Pawińska-Wasikowska K, Balwierz W.

Przegl Lek. 2010;67(6):361-5. Polish.

PMID:
21344762
10.

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

Dworzak MN, Fröschl G, Printz D, Mann G, Pötschger U, Mühlegger N, Fritsch G, Gadner H; Austrian Berlin-Frankfurt-Münster Study Group.

Blood. 2002 Mar 15;99(6):1952-8.

11.

Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.

Vidriales MB, Pérez JJ, López-Berges MC, Gutiérrez N, Ciudad J, Lucio P, Vazquez L, García-Sanz R, del Cañizo MC, Fernández-Calvo J, Ramos F, Rodríguez MJ, Calmuntia MJ, Porwith A, Orfao A, San-Miguel JF.

Blood. 2003 Jun 15;101(12):4695-700. Epub 2003 Feb 13.

12.

Therapy response correlates with ALDH activity in ALDH low-positive childhood acute lymphoblastic leukemias.

Ahlers J, Witte KE, Schwarze CP, Lang P, Handgretinger R, Ebinger M.

Pediatr Hematol Oncol. 2014 May;31(4):303-10. doi: 10.3109/08880018.2013.859189. Epub 2013 Dec 5.

PMID:
24308780
13.

Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia.

George AA, Franklin J, Kerkof K, Shah AJ, Price M, Tsark E, Bockstoce D, Yao D, Hart N, Carcich S, Parkman R, Crooks GM, Weinberg K.

Blood. 2001 Jun 15;97(12):3925-30. Erratum in: Blood 2001 Sep 15;98(6):1686.

14.

Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia.

Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Pui CH, Campana D.

Blood. 2002 Jul 1;100(1):52-8.

15.
16.

Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.

DiGiuseppe JA, Fuller SG, Borowitz MJ.

Cytometry B Clin Cytom. 2009 Mar;76(2):150-5. doi: 10.1002/cyto.b.20440.

17.

Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.

van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ.

Leukemia. 2007 Aug;21(8):1700-7. Epub 2007 May 24.

PMID:
17525725
18.

[Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].

Liu YR, Wang H, Chang Y, Cheng YF, Fu JY, Zhang LP, Liu GL, Chen SS.

Zhonghua Xue Ye Xue Za Zhi. 2005 Jun;26(6):327-31. Chinese.

PMID:
16185473
19.

Adult and childhood acute lymphoblastic leukemia: clinico-biological differences based on CD34 antigen expression.

Cascavilla N, Musto P, D'Arena G, Ladogana S, Matera R, Carotenuto M.

Haematologica. 1997 Jan-Feb;82(1):31-7.

20.

Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.

Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B, Paluszewska M, Seferynska I, Lewandowski K, Kielbinski M, Czyz A, Balana-Nowak A, Król M, Skotnicki AB, Jedrzejczak WW, Warzocha K, Lange A, Hellmann A.

Br J Haematol. 2008 Jun;142(2):227-37. doi: 10.1111/j.1365-2141.2008.07185.x. Epub 2008 May 19.

PMID:
18492099

Supplemental Content

Support Center